Articles related to BLOOD CANCERS

Uncover the potential of nivolumab and axicabtagene ciloleucel as they showcase promising results in the latest lymphoma trials, potentially reshaping the standard of care for these malignancies.

The MAJIC-PV study offers new insights into the use of ruxolitinib for polycythemia vera patients intolerant to hydroxycarbamide, emphasizing its role in extending survival and improving response rates.

Bispecific antibodies are molecules that are designed to engage or bind to two distinct targets, bringing two distinct cells together. The majority of those that have received regulatory approval are T-cell-engaging bispecific antibodies. Blinatumomab (Blincyto) for ALL, teclistamab (Tecvayli) for multiple myeloma, and mosunetuzumab-axgb (Lunsumio) for follicular lymphoma are some examples of FDA-approved treatments. Glofitamab, another bispecific antibody, is currently under FDA Priority Review for the treatment of R/R DLBCL. Another type of immunotherapy is chimeric antigen receptor (CAR) T-cell therapy, but bispecific antibodies provide the same spectrum of side effects with much less toxicity and are showing promise in solid tumors as well.

Acquired/congenital bone marrow failure, thalassemia/hemoglobinopathies, transfusion medicine, new therapies (pharmacology), infections of the immunocompromised, hematologic malignancies (acute/chronic leukemias; myeloma/lymphomas), thoracic oncology (head/neck/lung/thyroid), and many other practice improvement areas are covered in this CME activity worth up to 41.25 credits. The video curriculum starts at $1,795 in price.

In this extensive survey, patients with hematologic malignancies who have breakthrough COVID-19 have approximately 9% reduced mortality rate than they did before vaccination. Patients who received monoclonal antibodies, either alone or in conjunction with antivirals, had superior clinical results.

We can better understand outcomes in patients with a variety of ages, ethnicities, comorbidities, and exposures by using observational data. It can be challenging or even impossible to disentangle the diverse effects of dynamic elements like vaccination rates, patient behaviors, and COVID-19 pathogenicity. Randomized controlled trials involving blood cancer patients are required to fully assess the impact of COVID-19 therapies. The impact of both bivalent vaccines and prophylactic monoclonal antibodies, as well as ways to assure equitable distribution of COVID-19 vaccines and therapies, will all be determined by future study. Some of those studies must involve people who have hematologic malignancies.